The personal users segment by end user is estimated to lead the market growth during the forecast period.

According to a new market research study of “Europe Mobile ECG Devices Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Modality, End User and Country.” The Europe mobile ECG devices market is expected to reach US$ 621.40 million by 2028 from US$ 453.93 million in 2021; it is estimated to grow at a CAGR of 4.6% from 2021 to 2028. The report highlights trends prevailing in the Europe mobile ECG devices market and the factors driving market along with those that act as hindrances.

Unhealthy diet is one of the most important lifestyle factors leading to cardiovascular diseases. The increasing prevalence of cardiovascular diseases, and the consequently rising need for the continuous monitoring of ECG levels to provide accurate analysis, propel the demand for mobile ECG devices. ECG systems are the most effective instruments for detecting arrhythmias (abnormal heart rhythm), coronary artery disease, atrial fibrillation, previous heart attack, and other conditions. According to the World Health Organization (WHO), CVDs are the leading cause of death worldwide, with 17.9 million deaths caused in the world each year; moreover, 30 million people suffer from stroke every year. According to the WHO factsheets, ~17.7 million people died due to CVDs in 2017, of which ~7.4 million mortalities were due to coronary heart disease and 6.7 million were due to stroke. The European Society of Cardiology reported that atrial fibrillation is a commonly found condition in the region, and the patients suffering from atrial fibrillation are at a five-times greater risk of getting a stroke. Along with the increasing incidence of cardiac diseases and the need to reduce hospital stays of patients, which otherwise require a long-term care, there is a surge in demand for mobile ECG devices.  Mobile ECG devices are inexpensive, disposable, and easy to use compared to traditional ECG equipment.

The European region is severely affected by the exponential growth in COVID-19 cases. As per the European Centre for Disease Prevention and Control (ECDC), social restrictions were reintroduced after the onset of the second wave of COVID-19 in the UK, Spain, and Italy. The recurrent surge in cases with uncertain intervals has been hampering healthcare sectors in European countries. The mobile ECG devices market witnessed shortcomings at the beginning of the COVID-19 crisis due to disruption in the supply chain, slump in demand, and disturbances in manufacturing and operations. Additionally, medical appointments and surgeries were delayed in many clinics in Europe. The impact of pandemic was also seen on the new product launches and ongoing clinical trials of medical devices, resulting in decreased sales of mobile ECG devices in the region. However, with the implementation of proper guidelines and following protocols to reduce SARS-CoV-2 exposure, and bringing restrictions on movements to ease, the market is expected to resurge during the forecast period.

The Europe mobile ECG devices market, based on type, has been segmented into monitoring ECG systems and diagnostic ECG systems. The Europe mobile ECG devices market, based on application, is segmented into handheld, band, pen, and others. The Europe mobile ECG devices market, based on end user, is segmented into personal users, hospitals and clinics, and ambulatory services. Geographically, the Europe mobile ECG devices market is sub-segmented into Germany, Spain, Italy, UK, France and Rest of Europe.

THOR, Koninklijke Philips N.V., Bittium Biosignals LTD. (Subsidiary of Bittium Corporation), Medtronic, AliveCor, Inc, Nihon Kohden Corporation, EB Neuro S.P.A and Cardiocity Limited are among the leading companies operating in the Europe mobile ECG devices market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com